Global Somatostatin Analogue Drug Market 2023 by Company, Regions, Type and Application, Forecast to 2029

Page: 104

Published Date: 26 Feb 2023

Category: Pharma & Healthcare

PDF Download

Get FREE Sample

Customize Request

Description
Table of Contents
Table of Figures
Research Methodology
Related Reports
Product Tags

Description

Somatostatin analogues are drugs that stop your body from making too many hormones. Some neuroendocrine tumours (NETs) make large amounts of hormones that cause a group of symptoms called carcinoid syndrome. Somatostatin analogues are a possible treatment for people with carcinoid syndrome.

According to our (Global Info Research) latest study, the global Somatostatin Analogue Drug market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

This report is a detailed and comprehensive analysis for global Somatostatin Analogue Drug market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.

Key Features:
Global Somatostatin Analogue Drug market size and forecasts, in consumption value ($ Million), 2018-2029
Global Somatostatin Analogue Drug market size and forecasts by region and country, in consumption value ($ Million), 2018-2029
Global Somatostatin Analogue Drug market size and forecasts, by Type and by Application, in consumption value ($ Million), 2018-2029
Global Somatostatin Analogue Drug market shares of main players, in revenue ($ Million), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Somatostatin Analogue Drug
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Somatostatin Analogue Drug market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Camurus AB, Chiasma, Ipsen Group, Boehringer Ingelheim International GmbH and Eli Lilly & Co., etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.

Market segmentation
Somatostatin Analogue Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provide accurate calculations and forecasts for consumption value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Octreotide
Lanreotide
Pasireotide

Market segment by Application
Acromegaly
Neuroendocrine Tumor (NET)
Others

Market segment by players, this report covers
Camurus AB
Chiasma
Ipsen Group
Boehringer Ingelheim International GmbH
Eli Lilly & Co.
F. Hoffmann-La Roche Ltd.
Novartis AG
Pfizer Inc.
Tarveda Therapeutics Inc.
Teva Pharmaceutical Industries Ltd.

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Somatostatin Analogue Drug product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Somatostatin Analogue Drug, with revenue, gross margin and global market share of Somatostatin Analogue Drug from 2018 to 2023.
Chapter 3, the Somatostatin Analogue Drug competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Somatostatin Analogue Drug market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War
Chapter 12, the key raw materials and key suppliers, and industry chain of Somatostatin Analogue Drug.
Chapter 13, to describe Somatostatin Analogue Drug research findings and conclusion.

Table of Contents

1 Market Overview
    1.1 Product Overview and Scope of Somatostatin Analogue Drug
    1.2 Market Estimation Caveats and Base Year
    1.3 Classification of Somatostatin Analogue Drug by Type
        1.3.1 Overview: Global Somatostatin Analogue Drug Market Size by Type: 2018 Versus 2022 Versus 2029
        1.3.2 Global Somatostatin Analogue Drug Consumption Value Market Share by Type in 2022
        1.3.3 Octreotide
        1.3.4 Lanreotide
        1.3.5 Pasireotide
    1.4 Global Somatostatin Analogue Drug Market by Application
        1.4.1 Overview: Global Somatostatin Analogue Drug Market Size by Application: 2018 Versus 2022 Versus 2029
        1.4.2 Acromegaly
        1.4.3 Neuroendocrine Tumor (NET)
        1.4.4 Others
    1.5 Global Somatostatin Analogue Drug Market Size & Forecast
    1.6 Global Somatostatin Analogue Drug Market Size and Forecast by Region
        1.6.1 Global Somatostatin Analogue Drug Market Size by Region: 2018 VS 2022 VS 2029
        1.6.2 Global Somatostatin Analogue Drug Market Size by Region, (2018-2029)
        1.6.3 North America Somatostatin Analogue Drug Market Size and Prospect (2018-2029)
        1.6.4 Europe Somatostatin Analogue Drug Market Size and Prospect (2018-2029)
        1.6.5 Asia-Pacific Somatostatin Analogue Drug Market Size and Prospect (2018-2029)
        1.6.6 South America Somatostatin Analogue Drug Market Size and Prospect (2018-2029)
        1.6.7 Middle East and Africa Somatostatin Analogue Drug Market Size and Prospect (2018-2029)

2 Company Profiles
    2.1 Camurus AB
        2.1.1 Camurus AB Details
        2.1.2 Camurus AB Major Business
        2.1.3 Camurus AB Somatostatin Analogue Drug Product and Solutions
        2.1.4 Camurus AB Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.1.5 Camurus AB Recent Developments and Future Plans
    2.2 Chiasma
        2.2.1 Chiasma Details
        2.2.2 Chiasma Major Business
        2.2.3 Chiasma Somatostatin Analogue Drug Product and Solutions
        2.2.4 Chiasma Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.2.5 Chiasma Recent Developments and Future Plans
    2.3 Ipsen Group
        2.3.1 Ipsen Group Details
        2.3.2 Ipsen Group Major Business
        2.3.3 Ipsen Group Somatostatin Analogue Drug Product and Solutions
        2.3.4 Ipsen Group Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.3.5 Ipsen Group Recent Developments and Future Plans
    2.4 Boehringer Ingelheim International GmbH
        2.4.1 Boehringer Ingelheim International GmbH Details
        2.4.2 Boehringer Ingelheim International GmbH Major Business
        2.4.3 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product and Solutions
        2.4.4 Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.4.5 Boehringer Ingelheim International GmbH Recent Developments and Future Plans
    2.5 Eli Lilly & Co.
        2.5.1 Eli Lilly & Co. Details
        2.5.2 Eli Lilly & Co. Major Business
        2.5.3 Eli Lilly & Co. Somatostatin Analogue Drug Product and Solutions
        2.5.4 Eli Lilly & Co. Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.5.5 Eli Lilly & Co. Recent Developments and Future Plans
    2.6 F. Hoffmann-La Roche Ltd.
        2.6.1 F. Hoffmann-La Roche Ltd. Details
        2.6.2 F. Hoffmann-La Roche Ltd. Major Business
        2.6.3 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product and Solutions
        2.6.4 F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.6.5 F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
    2.7 Novartis AG
        2.7.1 Novartis AG Details
        2.7.2 Novartis AG Major Business
        2.7.3 Novartis AG Somatostatin Analogue Drug Product and Solutions
        2.7.4 Novartis AG Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.7.5 Novartis AG Recent Developments and Future Plans
    2.8 Pfizer Inc.
        2.8.1 Pfizer Inc. Details
        2.8.2 Pfizer Inc. Major Business
        2.8.3 Pfizer Inc. Somatostatin Analogue Drug Product and Solutions
        2.8.4 Pfizer Inc. Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.8.5 Pfizer Inc. Recent Developments and Future Plans
    2.9 Tarveda Therapeutics Inc.
        2.9.1 Tarveda Therapeutics Inc. Details
        2.9.2 Tarveda Therapeutics Inc. Major Business
        2.9.3 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product and Solutions
        2.9.4 Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.9.5 Tarveda Therapeutics Inc. Recent Developments and Future Plans
    2.10 Teva Pharmaceutical Industries Ltd.
        2.10.1 Teva Pharmaceutical Industries Ltd. Details
        2.10.2 Teva Pharmaceutical Industries Ltd. Major Business
        2.10.3 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product and Solutions
        2.10.4 Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue, Gross Margin and Market Share (2018-2023)
        2.10.5 Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans

3 Market Competition, by Players
    3.1 Global Somatostatin Analogue Drug Revenue and Share by Players (2018-2023)
    3.2 Market Share Analysis (2022)
        3.2.1 Market Share of Somatostatin Analogue Drug by Company Revenue
        3.2.2 Top 3 Somatostatin Analogue Drug Players Market Share in 2022
        3.2.3 Top 6 Somatostatin Analogue Drug Players Market Share in 2022
    3.3 Somatostatin Analogue Drug Market: Overall Company Footprint Analysis
        3.3.1 Somatostatin Analogue Drug Market: Region Footprint
        3.3.2 Somatostatin Analogue Drug Market: Company Product Type Footprint
        3.3.3 Somatostatin Analogue Drug Market: Company Product Application Footprint
    3.4 New Market Entrants and Barriers to Market Entry
    3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type
    4.1 Global Somatostatin Analogue Drug Consumption Value and Market Share by Type (2018-2023)
    4.2 Global Somatostatin Analogue Drug Market Forecast by Type (2024-2029)

5 Market Size Segment by Application
    5.1 Global Somatostatin Analogue Drug Consumption Value Market Share by Application (2018-2023)
    5.2 Global Somatostatin Analogue Drug Market Forecast by Application (2024-2029)

6 North America
    6.1 North America Somatostatin Analogue Drug Consumption Value by Type (2018-2029)
    6.2 North America Somatostatin Analogue Drug Consumption Value by Application (2018-2029)
    6.3 North America Somatostatin Analogue Drug Market Size by Country
        6.3.1 North America Somatostatin Analogue Drug Consumption Value by Country (2018-2029)
        6.3.2 United States Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        6.3.3 Canada Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        6.3.4 Mexico Somatostatin Analogue Drug Market Size and Forecast (2018-2029)

7 Europe
    7.1 Europe Somatostatin Analogue Drug Consumption Value by Type (2018-2029)
    7.2 Europe Somatostatin Analogue Drug Consumption Value by Application (2018-2029)
    7.3 Europe Somatostatin Analogue Drug Market Size by Country
        7.3.1 Europe Somatostatin Analogue Drug Consumption Value by Country (2018-2029)
        7.3.2 Germany Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        7.3.3 France Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        7.3.4 United Kingdom Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        7.3.5 Russia Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        7.3.6 Italy Somatostatin Analogue Drug Market Size and Forecast (2018-2029)

8 Asia-Pacific
    8.1 Asia-Pacific Somatostatin Analogue Drug Consumption Value by Type (2018-2029)
    8.2 Asia-Pacific Somatostatin Analogue Drug Consumption Value by Application (2018-2029)
    8.3 Asia-Pacific Somatostatin Analogue Drug Market Size by Region
        8.3.1 Asia-Pacific Somatostatin Analogue Drug Consumption Value by Region (2018-2029)
        8.3.2 China Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        8.3.3 Japan Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        8.3.4 South Korea Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        8.3.5 India Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        8.3.6 Southeast Asia Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        8.3.7 Australia Somatostatin Analogue Drug Market Size and Forecast (2018-2029)

9 South America
    9.1 South America Somatostatin Analogue Drug Consumption Value by Type (2018-2029)
    9.2 South America Somatostatin Analogue Drug Consumption Value by Application (2018-2029)
    9.3 South America Somatostatin Analogue Drug Market Size by Country
        9.3.1 South America Somatostatin Analogue Drug Consumption Value by Country (2018-2029)
        9.3.2 Brazil Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        9.3.3 Argentina Somatostatin Analogue Drug Market Size and Forecast (2018-2029)

10 Middle East & Africa
    10.1 Middle East & Africa Somatostatin Analogue Drug Consumption Value by Type (2018-2029)
    10.2 Middle East & Africa Somatostatin Analogue Drug Consumption Value by Application (2018-2029)
    10.3 Middle East & Africa Somatostatin Analogue Drug Market Size by Country
        10.3.1 Middle East & Africa Somatostatin Analogue Drug Consumption Value by Country (2018-2029)
        10.3.2 Turkey Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        10.3.3 Saudi Arabia Somatostatin Analogue Drug Market Size and Forecast (2018-2029)
        10.3.4 UAE Somatostatin Analogue Drug Market Size and Forecast (2018-2029)

11 Market Dynamics
    11.1 Somatostatin Analogue Drug Market Drivers
    11.2 Somatostatin Analogue Drug Market Restraints
    11.3 Somatostatin Analogue Drug Trends Analysis
    11.4 Porters Five Forces Analysis
        11.4.1 Threat of New Entrants
        11.4.2 Bargaining Power of Suppliers
        11.4.3 Bargaining Power of Buyers
        11.4.4 Threat of Substitutes
        11.4.5 Competitive Rivalry
    11.5 Influence of COVID-19 and Russia-Ukraine War
        11.5.1 Influence of COVID-19
        11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis
    12.1 Somatostatin Analogue Drug Industry Chain
    12.2 Somatostatin Analogue Drug Upstream Analysis
    12.3 Somatostatin Analogue Drug Midstream Analysis
    12.4 Somatostatin Analogue Drug Downstream Analysis

13 Research Findings and Conclusion

14 Appendix
    14.1 Methodology
    14.2 Research Process and Data Source
    14.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Global Somatostatin Analogue Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Table 2. Global Somatostatin Analogue Drug Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
    Table 3. Global Somatostatin Analogue Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 4. Global Somatostatin Analogue Drug Consumption Value by Region (2024-2029) & (USD Million)
    Table 5. Camurus AB Company Information, Head Office, and Major Competitors
    Table 6. Camurus AB Major Business
    Table 7. Camurus AB Somatostatin Analogue Drug Product and Solutions
    Table 8. Camurus AB Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 9. Camurus AB Recent Developments and Future Plans
    Table 10. Chiasma Company Information, Head Office, and Major Competitors
    Table 11. Chiasma Major Business
    Table 12. Chiasma Somatostatin Analogue Drug Product and Solutions
    Table 13. Chiasma Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 14. Chiasma Recent Developments and Future Plans
    Table 15. Ipsen Group Company Information, Head Office, and Major Competitors
    Table 16. Ipsen Group Major Business
    Table 17. Ipsen Group Somatostatin Analogue Drug Product and Solutions
    Table 18. Ipsen Group Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 19. Ipsen Group Recent Developments and Future Plans
    Table 20. Boehringer Ingelheim International GmbH Company Information, Head Office, and Major Competitors
    Table 21. Boehringer Ingelheim International GmbH Major Business
    Table 22. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Product and Solutions
    Table 23. Boehringer Ingelheim International GmbH Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 24. Boehringer Ingelheim International GmbH Recent Developments and Future Plans
    Table 25. Eli Lilly & Co. Company Information, Head Office, and Major Competitors
    Table 26. Eli Lilly & Co. Major Business
    Table 27. Eli Lilly & Co. Somatostatin Analogue Drug Product and Solutions
    Table 28. Eli Lilly & Co. Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 29. Eli Lilly & Co. Recent Developments and Future Plans
    Table 30. F. Hoffmann-La Roche Ltd. Company Information, Head Office, and Major Competitors
    Table 31. F. Hoffmann-La Roche Ltd. Major Business
    Table 32. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Product and Solutions
    Table 33. F. Hoffmann-La Roche Ltd. Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 34. F. Hoffmann-La Roche Ltd. Recent Developments and Future Plans
    Table 35. Novartis AG Company Information, Head Office, and Major Competitors
    Table 36. Novartis AG Major Business
    Table 37. Novartis AG Somatostatin Analogue Drug Product and Solutions
    Table 38. Novartis AG Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 39. Novartis AG Recent Developments and Future Plans
    Table 40. Pfizer Inc. Company Information, Head Office, and Major Competitors
    Table 41. Pfizer Inc. Major Business
    Table 42. Pfizer Inc. Somatostatin Analogue Drug Product and Solutions
    Table 43. Pfizer Inc. Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 44. Pfizer Inc. Recent Developments and Future Plans
    Table 45. Tarveda Therapeutics Inc. Company Information, Head Office, and Major Competitors
    Table 46. Tarveda Therapeutics Inc. Major Business
    Table 47. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Product and Solutions
    Table 48. Tarveda Therapeutics Inc. Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 49. Tarveda Therapeutics Inc. Recent Developments and Future Plans
    Table 50. Teva Pharmaceutical Industries Ltd. Company Information, Head Office, and Major Competitors
    Table 51. Teva Pharmaceutical Industries Ltd. Major Business
    Table 52. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Product and Solutions
    Table 53. Teva Pharmaceutical Industries Ltd. Somatostatin Analogue Drug Revenue (USD Million), Gross Margin and Market Share (2018-2023)
    Table 54. Teva Pharmaceutical Industries Ltd. Recent Developments and Future Plans
    Table 55. Global Somatostatin Analogue Drug Revenue (USD Million) by Players (2018-2023)
    Table 56. Global Somatostatin Analogue Drug Revenue Share by Players (2018-2023)
    Table 57. Breakdown of Somatostatin Analogue Drug by Company Type (Tier 1, Tier 2, and Tier 3)
    Table 58. Market Position of Players in Somatostatin Analogue Drug, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
    Table 59. Head Office of Key Somatostatin Analogue Drug Players
    Table 60. Somatostatin Analogue Drug Market: Company Product Type Footprint
    Table 61. Somatostatin Analogue Drug Market: Company Product Application Footprint
    Table 62. Somatostatin Analogue Drug New Market Entrants and Barriers to Market Entry
    Table 63. Somatostatin Analogue Drug Mergers, Acquisition, Agreements, and Collaborations
    Table 64. Global Somatostatin Analogue Drug Consumption Value (USD Million) by Type (2018-2023)
    Table 65. Global Somatostatin Analogue Drug Consumption Value Share by Type (2018-2023)
    Table 66. Global Somatostatin Analogue Drug Consumption Value Forecast by Type (2024-2029)
    Table 67. Global Somatostatin Analogue Drug Consumption Value by Application (2018-2023)
    Table 68. Global Somatostatin Analogue Drug Consumption Value Forecast by Application (2024-2029)
    Table 69. North America Somatostatin Analogue Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 70. North America Somatostatin Analogue Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 71. North America Somatostatin Analogue Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 72. North America Somatostatin Analogue Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 73. North America Somatostatin Analogue Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 74. North America Somatostatin Analogue Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 75. Europe Somatostatin Analogue Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 76. Europe Somatostatin Analogue Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 77. Europe Somatostatin Analogue Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 78. Europe Somatostatin Analogue Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 79. Europe Somatostatin Analogue Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 80. Europe Somatostatin Analogue Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 81. Asia-Pacific Somatostatin Analogue Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 82. Asia-Pacific Somatostatin Analogue Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 83. Asia-Pacific Somatostatin Analogue Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 84. Asia-Pacific Somatostatin Analogue Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 85. Asia-Pacific Somatostatin Analogue Drug Consumption Value by Region (2018-2023) & (USD Million)
    Table 86. Asia-Pacific Somatostatin Analogue Drug Consumption Value by Region (2024-2029) & (USD Million)
    Table 87. South America Somatostatin Analogue Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 88. South America Somatostatin Analogue Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 89. South America Somatostatin Analogue Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 90. South America Somatostatin Analogue Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 91. South America Somatostatin Analogue Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 92. South America Somatostatin Analogue Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 93. Middle East & Africa Somatostatin Analogue Drug Consumption Value by Type (2018-2023) & (USD Million)
    Table 94. Middle East & Africa Somatostatin Analogue Drug Consumption Value by Type (2024-2029) & (USD Million)
    Table 95. Middle East & Africa Somatostatin Analogue Drug Consumption Value by Application (2018-2023) & (USD Million)
    Table 96. Middle East & Africa Somatostatin Analogue Drug Consumption Value by Application (2024-2029) & (USD Million)
    Table 97. Middle East & Africa Somatostatin Analogue Drug Consumption Value by Country (2018-2023) & (USD Million)
    Table 98. Middle East & Africa Somatostatin Analogue Drug Consumption Value by Country (2024-2029) & (USD Million)
    Table 99. Somatostatin Analogue Drug Raw Material
    Table 100. Key Suppliers of Somatostatin Analogue Drug Raw Materials
List of Figures
    Figure 1. Somatostatin Analogue Drug Picture
    Figure 2. Global Somatostatin Analogue Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 3. Global Somatostatin Analogue Drug Consumption Value Market Share by Type in 2022
    Figure 4. Octreotide
    Figure 5. Lanreotide
    Figure 6. Pasireotide
    Figure 7. Global Somatostatin Analogue Drug Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
    Figure 8. Somatostatin Analogue Drug Consumption Value Market Share by Application in 2022
    Figure 9. Acromegaly Picture
    Figure 10. Neuroendocrine Tumor (NET) Picture
    Figure 11. Others Picture
    Figure 12. Global Somatostatin Analogue Drug Consumption Value, (USD Million): 2018 & 2022 & 2029
    Figure 13. Global Somatostatin Analogue Drug Consumption Value and Forecast (2018-2029) & (USD Million)
    Figure 14. Global Market Somatostatin Analogue Drug Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
    Figure 15. Global Somatostatin Analogue Drug Consumption Value Market Share by Region (2018-2029)
    Figure 16. Global Somatostatin Analogue Drug Consumption Value Market Share by Region in 2022
    Figure 17. North America Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 18. Europe Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 19. Asia-Pacific Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 20. South America Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 21. Middle East and Africa Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 22. Global Somatostatin Analogue Drug Revenue Share by Players in 2022
    Figure 23. Somatostatin Analogue Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
    Figure 24. Global Top 3 Players Somatostatin Analogue Drug Market Share in 2022
    Figure 25. Global Top 6 Players Somatostatin Analogue Drug Market Share in 2022
    Figure 26. Global Somatostatin Analogue Drug Consumption Value Share by Type (2018-2023)
    Figure 27. Global Somatostatin Analogue Drug Market Share Forecast by Type (2024-2029)
    Figure 28. Global Somatostatin Analogue Drug Consumption Value Share by Application (2018-2023)
    Figure 29. Global Somatostatin Analogue Drug Market Share Forecast by Application (2024-2029)
    Figure 30. North America Somatostatin Analogue Drug Consumption Value Market Share by Type (2018-2029)
    Figure 31. North America Somatostatin Analogue Drug Consumption Value Market Share by Application (2018-2029)
    Figure 32. North America Somatostatin Analogue Drug Consumption Value Market Share by Country (2018-2029)
    Figure 33. United States Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 34. Canada Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 35. Mexico Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 36. Europe Somatostatin Analogue Drug Consumption Value Market Share by Type (2018-2029)
    Figure 37. Europe Somatostatin Analogue Drug Consumption Value Market Share by Application (2018-2029)
    Figure 38. Europe Somatostatin Analogue Drug Consumption Value Market Share by Country (2018-2029)
    Figure 39. Germany Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 40. France Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 41. United Kingdom Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 42. Russia Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 43. Italy Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 44. Asia-Pacific Somatostatin Analogue Drug Consumption Value Market Share by Type (2018-2029)
    Figure 45. Asia-Pacific Somatostatin Analogue Drug Consumption Value Market Share by Application (2018-2029)
    Figure 46. Asia-Pacific Somatostatin Analogue Drug Consumption Value Market Share by Region (2018-2029)
    Figure 47. China Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 48. Japan Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 49. South Korea Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 50. India Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 51. Southeast Asia Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 52. Australia Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 53. South America Somatostatin Analogue Drug Consumption Value Market Share by Type (2018-2029)
    Figure 54. South America Somatostatin Analogue Drug Consumption Value Market Share by Application (2018-2029)
    Figure 55. South America Somatostatin Analogue Drug Consumption Value Market Share by Country (2018-2029)
    Figure 56. Brazil Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 57. Argentina Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 58. Middle East and Africa Somatostatin Analogue Drug Consumption Value Market Share by Type (2018-2029)
    Figure 59. Middle East and Africa Somatostatin Analogue Drug Consumption Value Market Share by Application (2018-2029)
    Figure 60. Middle East and Africa Somatostatin Analogue Drug Consumption Value Market Share by Country (2018-2029)
    Figure 61. Turkey Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 62. Saudi Arabia Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 63. UAE Somatostatin Analogue Drug Consumption Value (2018-2029) & (USD Million)
    Figure 64. Somatostatin Analogue Drug Market Drivers
    Figure 65. Somatostatin Analogue Drug Market Restraints
    Figure 66. Somatostatin Analogue Drug Market Trends
    Figure 67. Porters Five Forces Analysis
    Figure 68. Manufacturing Cost Structure Analysis of Somatostatin Analogue Drug in 2022
    Figure 69. Manufacturing Process Analysis of Somatostatin Analogue Drug
    Figure 70. Somatostatin Analogue Drug Industrial Chain
    Figure 71. Methodology
    Figure 72. Research Process and Data Source

Research Methodology

Client Requirements

Review and analyze client requirements

Discussion of all the project requirements and queries

Flexibility Check

Project Feasibility Analysis

Finalizing tentative research programme

Structuring project proposal with scope, timeline, and costs

Analyzing Market Dynamics

Determination of key drivers, restraints, challenge, and opportunity

Identifies market needs and trends

Market Size Estimation & Forecast

Estimation of historical data based on secondary and primary data

Anticipating market recast by assigning weightage to market forces (drivers, restraints, opportunities)

Freezing historical and forecast market size estimations based on evolution, trends, outlook, and strategies

Consideration of geography, region-specific product/service demand for region segments

Consideration of product utilization rates, product demand outlook for segments by application or end-user.

Data Source

Secondary Source
Data collections from annual reports, presentations,associations, journals, analyst reports, paid database, press releases, blogs, newsletters,and GIR repositories.

Primary Source
Research discussion with manufacturers, distributors, suppliers, end user, industry experts to verify insights.

Validation and
triangulation of
secondary and primary source.

Collection of data

Cumulating and collating the essential qualitative and quantitative data

Generation of report in client requested format by research analysts

Reviews by expert analysts

Final quality check

Clarifying queries

Receiving feedback

Ensuring satisfaction

01 Identification of data

This step involves identification of several primary and secondary data research sources, including Global Info Research's internal data sources. The primary sources consist of in-depth discussions and interviews with policy makers, industry experts, and data evaluators, whereas secondary sources include a thorough study of market journals, press releases, annual reports, and government and non-government agencies websites.
02 Evaluation of Market Dynamic

This phase includes a detailed evaluation of several factors that are likely to affect the market dynamics. It involves a comprehensive assessment of major market pain points, drivers, and trends. It also comprises a detailed study of research plans and methodology.
03 Collection of Data

This process consists of gathering data, accessing proprietary databases, and reaching out to key industry participants that operate in the market across the value chain. It also involves studying several patterns in the historical data and comparing it with the current scenario.
04 Collaboration of Data

This stage involves the validation of data and arrival at actual statistics, and evolution of the market over the years. It entails the study and analyzes various segments and verticals of the market. An impact analysis is also performed to observe which factors will affect the market in the next few years.
05 Verification and Analysis

This is the final stage, which involves both quantity and quality checks. Although the process of data verification is an integral part of the research process, all data points and statistics and figures are re-checked to uphold their authenticity and validity.

Related Reports

Global Somatostatin Analogue Drug Supply, Demand and Key Producers, 2023-2029

Global Somatostatin Analogue Drug Supply, Demand and Key Producers, 2023-2029

date 01 Feb 2023

date Pharma & Healthcare

The global Somatostatin Analogue Drug market size is expected to reach $ million by 2029, rising at a market growth of % CAGR during the forecast period (2023-2029).

Global Somatostatin Analogue Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Somatostatin Analogue Drug Market 2024 by Company, Regions, Type and Application, Forecast to 2030

date 02 Jan 2024

date Pharma & Healthcare

According to our (Global Info Research) latest study, the global Somatostatin Analogue Drug market size was valued at USD 6132.5 million in 2023 and is forecast to a readjusted size of USD 9534.6 million by 2030 with a CAGR of 6.5% during review period.

Product Tags

Somatostatin Analogue Drug

GABA Supplements

L-carnitine Capsule

Opical Thrombin

Purchase Options

Single User License

USD3480.00

Multi User License

USD5220.00

Corporate Users License

USD6960.00

Add To Cart

Buy Now

Popular Product Keywords

AI
semiconductor
electron
5G
artificial intelligence
Battery
new energy
We Provide Professional, Accurate Market Analysis to Help You Stay Ahead of Your Competition.

Speak to our analyst >>
Our Clients
What We Can Provide?

With better results and higher quality products,Our professional reports can achieve four things:
- Insight into the industry market information
- Analyze market development needs
- Prospects for future development
- Develop industry investment strategy
Digging deeper into global industry information and providing market strategies.

Contact Us >>